Hyperimmune IgY, Developed for Targeted Applications

Explore IgY ingredient programs and develop finished supplements through a focused OEM process.

The IgY platform

From an application brief to an ingredient plan.

IgY is an antibody found in egg yolk. Define the intended use, ingredient profile and format before development begins.

Start an ingredient brief Conceptual translucent IgY-shaped form rising from an egg yolk
01 / DEFINEDefine the brief

Set the application family, target market and formulation needs.

Start an ingredient brief
02 / DEVELOPChoose an ingredient direction

Review the IgY family, target strategy and powder-format requirements.

Explore ingredient programs
03 / CHARACTERIZEBuild a technical profile

Set binding and quality criteria relevant to the intended use.

Review quality & documentation
04 / FORMULATEEvaluate finished format

Assess material properties, formulation fit and next-stage validation.

Explore OEM formats View application cases
Market insights / Product audience

From market signals to an application brief.

Map the end user, route to market and product requirements before choosing an ingredient program or finished-product format.

Consumer signalsEight family briefsWHO resistance context
Explore the data, sources and application opportunities
01 / DEMANDDefine the opportunity

Identify the wellness category, intended user and questions a product should answer.

02 / FITAssess application fit

Compare ingredient direction, dosage format and supporting technical evidence.

03 / MARKETPlan the route to market

Review channel, claims, labeling and documentation for the intended destination.

Consumer survey / U.S.

Gut and immune wellness: signals to investigate.

These figures describe supplement users and adjacent categories. They are inputs to a product brief, not an estimate of IgY sales or efficacy.

GUT CATEGORY / PREBIOTICS

Reported use among supplement users

Bar scale: 0–10%
2023
5%
2024
7%

Two survey snapshots; the difference is not a forecast or a measured IgY trend.

Explore gut & microbiome ingredients
IMMUNE WELLNESS / MOTIVATION
30%of U.S. supplement users cited immune health as a reason for taking supplements in 2024.

A consumer motivation, not product performance or the share buying an IgY ingredient.

Explore immune wellness ingredients
Source: Council for Responsible Nutrition, 2024 Consumer Survey (Ipsos; published October 29, 2024). U.S. online survey of 3,194 adults, including 2,332 supplement users. The 2023 prebiotic value is the prior-year comparison reported in the 2024 release; the immune-health value is a 2024 response. These measures use different definitions, and no statistical-significance or IgY market-size claim is made.
Digestive wellness / Consumer self-care

Why consumers explore gut-health supplements.

U.S. survey responses about probiotics offer an adjacent-category signal for natural and non-prescription wellness concepts. They do not measure demand for IgY or show that a supplement treats a gut disorder.

ADJACENT CATEGORY / 202216%

of surveyed U.S. supplement users reported taking a probiotic. This uses a different denominator from the reasons at left.

Explore gut & microbiome directions
Source: Council for Responsible Nutrition, 2022 Consumer Survey on Dietary Supplements (reported November 1, 2022). The three reasons refer to probiotic users and can overlap; they should not be summed. This survey concerns probiotics, not IgY, clinical outcomes, a market-size estimate or a growth forecast.
Research context: how common are gut–brain interaction disorders?

A Rome Foundation study surveyed 73,076 adults across 33 countries. Rome IV criteria for at least one functional gastrointestinal disorder (now termed a disorder of gut–brain interaction) were met by 40.3% of internet-survey respondents and 20.7% of household-survey respondents. The methods and estimates differ and are reported separately.

This clinical burden describes a healthcare need, not a population eligible for supplements or an IgY market. Diagnosis and treatment require appropriate clinical care; any ingredient-specific benefit needs its own evidence.

Source: Rome Foundation Global Epidemiology Study, Sperber et al., Gastroenterology 2021.

Eight ingredient families / Opportunity briefs

Explore the need behind each direction.

Open a family to compare its evidence signal with a B2B development brief. Population burden, consumer interest and an IgY product’s potential are different measures; these families are not ranked by market size.

01 / FAMILYStomach wellness43.1%Estimated global H. pylori prevalence in studies from 2011–22Clinical prevalence / 2023 meta-analysis

Evidence signalH. pylori infection is a common cause of gastritis. Separately, the probiotic survey above shows interest in GI support; it does not measure stomach-specific or IgY demand.

B2B development routeExplore an adult stomach-wellness ingredient brief, format and target-specific evidence requirements.

Claim boundaryDiagnosed H. pylori infection and gastritis require clinical evaluation and treatment; this is not an eradication or gastritis claim.

Background sources: Li et al.: H. pylori global meta-analysis, 2023 NIDDK: Gastritis & gastropathy CRN: 2022 probiotic survey
Explore Stomach wellness ingredients
02 / FAMILYGut & microbiome61%of surveyed U.S. probiotic users cited GI support in 2022Consumer motivation / 2022

Evidence signalThe Rome Foundation documents substantial gut–brain interaction disorder burden; the probiotic survey above identifies GI support as a consumer motivation.

B2B development routeCompare gut-wellness powder, capsule and microbiome-oriented briefs with ingredient-specific studies and clear audience definitions.

Claim boundaryClinical disorder prevalence is not the addressable supplement market; no treatment or microbiome-modulation result is implied.

Background sources: Rome Foundation: Global study CRN: 2022 probiotic survey
Explore Gut & microbiome ingredients
03 / FAMILYOral wellness3.7Bpeople worldwide estimated to live with oral diseasesPopulation burden / WHO fact sheet

Evidence signalWHO describes a large global burden of oral disease and a need for prevention and routine oral care.

B2B development routeAssess daily oral-care formats and an oral-health audience with dental partners, suitable use instructions and substantiated claims.

Claim boundaryOral-care concepts do not imply prevention or treatment of cavities, gum disease or oral infection.

Background sources: WHO: Oral health fact sheet
Explore Oral wellness ingredients
04 / FAMILYMetabolic wellness43%of adults worldwide were overweight, including obesity, in 2022Population prevalence / 2022

Evidence signalWHO reports widespread overweight and obesity; this burden can inform audience research, but does not quantify demand for an IgY ingredient.

B2B development routeScope nutrition and lifestyle-support positioning, delivery format and measurable research questions for metabolic wellness.

Claim boundaryDo not infer weight loss, glucose control or obesity treatment from the population figures.

Background sources: WHO: Obesity and overweight
Explore Metabolic wellness ingredients
05 / FAMILYGut–liver axis1.7Bpeople worldwide estimated to live with steatotic liver diseasePopulation burden / WHO 2026

Evidence signalWHO recognizes steatotic liver disease as a growing noncommunicable-disease burden. A gut–liver formulation remains a separate research hypothesis.

B2B development routeDiscuss target definition, preclinical rationale and evidence milestones before considering a supplement concept.

Claim boundaryLiver-disease burden does not establish IgY benefit or justify a fatty-liver treatment claim.

Background sources: WHO: 2026 World Health Assembly update
Explore Gut–liver axis ingredients
06 / FAMILYBeauty wellness22%of surveyed U.S. supplement users cited hair, skin and nail health in 2020Consumer motivation / 2020

Evidence signalCRN reported skin, hair and nail health as a reason for supplement use in its 2020 U.S. survey; the 2024 survey also described greater interest among women.

B2B development routeExplore an ingestible-beauty audience, format and evidence plan for a BeautyGlow-style formulation concept.

Claim boundaryThe survey describes consumer motivation; it does not show an IgY skin, hair or nail outcome.

Background sources: CRN: 2020 consumer survey CRN: 2024 consumer survey
Explore Beauty wellness ingredients
07 / FAMILYFemale Health23–29%BV prevalence across studied populations of reproductive-age womenClinical prevalence / WHO 2025

Evidence signalWHO describes bacterial vaginosis prevalence across studied populations of reproductive-age women; NIH has funded vaginal-microbiome research.

B2B development routeDefine life stage, intended use and site-specific evidence for an exploratory intimate-wellness brief.

Claim boundaryA wellness ingredient is not a treatment or prevention claim for BV or another infection.

Background sources: WHO: Bacterial vaginosis fact sheet NIH: Human Microbiome Project research
Explore Female Health ingredients
08 / FAMILYImmune wellness30%of surveyed U.S. supplement users cited immune health in 2024Consumer motivation / 2024

Evidence signalIn CRN’s 2024 U.S. survey, 30% of supplement users cited immune health as a reason for supplement use.

B2B development routeSegment adult, senior and child-oriented briefs by format, age suitability and evidence for the finished formula.

Claim boundaryConsumer motivation is not evidence that IgY prevents infection or improves immune outcomes.

Background sources: CRN: 2024 consumer survey
Explore Immune wellness ingredients

These sourced signals guide market discovery and research prioritization. They are not sales forecasts or evidence of IgY efficacy. Product-specific specifications, intended market and claims require review for each project.

IGY APPLICATION LENS / PASSIVE ANTIBODY STRATEGYNon-antibiotic, target-defined IgY development.

Hyperimmune IgY is a passive antibody approach that can be developed against defined targets. Gut microbial balance is an application question for each ingredient and formula; consumer surveys and resistance statistics do not establish an IgY product benefit.

Explore the IgY platform
Explore the broader U.S. supplement-use trend
U.S. supplement landscape

A broader market signal.

Share of U.S. adults age 20+ reporting use of any dietary supplement in the past 30 days.

+6.4percentage points
2013–14 to 2021–23
Percent of adults · 0–70% scale
  1. 53.8%
    2013–14
  2. 55.9%
    2015–16
  3. 58.5%
    2017–20*
  4. 60.2%
    2021–23*
View audience context by age

In the August 2021–August 2023 survey, reported supplement use was 46.3% for ages 20–39, 60.3% for ages 40–59 and 75.9% for ages 60+.

These figures can inform audience planning. They do not measure demand for IgY.

Source: U.S. National Center for Health Statistics, NHANES Data Brief 561 (May 2026), Figure 4 and Figure 2. *Survey periods were 2017–March 2020 and August 2021–August 2023. These data describe dietary supplements overall; they are not IgY sales, market size or a forecast.

Who we work with

Open a buyer profile to see the typical starting brief.

01 / BRANDSSupplement brands

Develop a wellness concept around a defined audience, format and positioning.

Explore application cases
02 / MANUFACTURERSOEM & private label teams

Discuss ingredient suitability, formulation options and production requirements.

Build an OEM brief
03 / DISTRIBUTORSIngredient distributors

Review ingredient families, technical materials, target markets and commercial terms.

Browse IgY ingredients

End-user directions: stomach wellness, gut & microbiome, oral wellness, metabolic wellness, gut–liver axis, beauty, female health and immune wellness. These are starting points for market evaluation, not claims about a finished product.

Match an audience to an ingredient family
IgY ingredient programs

Start with an application family.

Eight directions for a focused ingredient brief. Specific targets and availability are reviewed with your team.

Unbranded powder sample and egg representing an IgY ingredient concept
01 / FAMILYStomach wellnessExplore 02 / FAMILYGut & microbiomeExplore 03 / FAMILYOral wellnessExplore 04 / FAMILYMetabolic wellnessExplore 05 / FAMILYGut–liver axisExplore 06 / FAMILYBeauty wellnessExplore 07 / FAMILYFemale HealthExplore 08 / FAMILYImmune wellnessExplore

Family names are development pathways. They do not represent a confirmed list of ready-to-ship IgY powders.

Browse all families
From ingredient to format

Application cases.

Examples of how IgY can be explored in finished supplement formats. Select an area to view relevant concepts, then open the related ingredient family.

Browse application examples by category.

Images illustrate formulation directions. Product status, ingredient availability, specifications and permitted claims depend on the market and project scope.

Technical & quality review

Ask for the data behind the ingredient.

A technical review can cover composition, IgY titer, protein, moisture, microbiological and storage criteria. Request the current specification and lot documentation for the material under review.

Request technical information
DOCUMENTATION TO DISCUSS
  • 01
    Ingredient specification Identity, composition and test methods
  • 02
    Certificate of Analysis Current lot results and acceptance criteria
  • 03
    Safety & quality records Microbiological results, allergen information and handling
  • 04
    Market documentation Export and registration needs by destination

Document availability and specifications depend on the selected program and market.

B2B partnership

A clearer path from concept to supply.

We bring the technical brief, application direction and commercial discussion into the same development process.

01 / FOCUS

Target-led scoping

Start with an application and technical question, then identify the right IgY development direction.

02 / TRANSLATION

Ingredient to format

Connect an ingredient family with the formulation, presentation and audience of a finished concept.

03 / COLLABORATION

Defined decision points

Agree on evaluation criteria, required documents and next milestones with the project team.

Supply / Qualification / Delivery

Commercial terms made reviewable.

Share your volume, target market and requested date. We will define the applicable production and delivery terms in a written project proposal.

Discuss supply requirements
Production capacity
Capacity and batch planning are scoped to the material specification, order volume and delivery schedule for each program.
Company & facility qualifications
Legal entity details, relevant facility credentials and available quality documents can be reviewed for the selected program and market.
Lead time
A production timetable is confirmed in the written quotation after formula, quantity and packaging are agreed.
Shipping & logistics
Shipping method, handling requirements, destination documents and delivery milestones are agreed for each order.
OEM / ODM development

From IgY ingredient to finished product.

Build a practical brief in three choices. Start with an application, then define the formula and dosage form.

Unbranded capsules and sachets illustrating possible supplement formats
01 / APPLICATION

Choose a theme

Select one of eight wellness families or describe a new direction.

02 / FORMULA

Shape the blend

Start with IgY alone, IgY with probiotics or a custom formula.

03 / FORMAT

Plan the product

Compare capsules, sachets, chewables and other formats.

Choose an application to start
Stomach wellness Gut & microbiome Oral wellness New direction View all options
Continue to the OEM project builder
OEM project builder

Build a starting brief.

Choose a direction in three steps. Your selections will be included in the inquiry email.

01 / Theme02 / Ingredients03 / Format04 / Contact
01 / Select an application theme

Choose an IgY direction or bring a new brief.

Explore ingredient programs ↗View application cases ↗
02 / Select an ingredient concept

These are starting points for a formulation discussion; specifications and availability are confirmed for each project.

Review IgY ingredient families ↗Quality & documentation ↗
03 / Select a format

Select a preferred format. We can review feasibility, packaging and market requirements together.

See format examples ↗
04 / Send a project inquiry

We will use the selections below to route your project discussion.

Your inquiry details are emailed to GenoScan for a reply.

These choices form a discussion brief. Formula feasibility, ingredient availability, specifications, minimum volumes and production terms are confirmed for each project.

Custom polyclonal IgY

A defined target. A custom IgY brief.

Share the intended application and desired output. We will review target strategy, feasibility and technical criteria.

INGREDIENT OUTPUTCustom IgY powderTarget rationale, powder profile and characterization needs. FINISHED CONCEPTCustom IgY in a productTarget-defined ingredient with an OEM formulation path.

Start with technical scoping. Formula, volume and packaging choices are handled in the OEM development process. Discuss confidential target details through an agreed channel.

Send a short technical brief
CUSTOM IGY TECHNICAL BRIEF

Share a technical starting point.

Select an output and describe the intended application. You can leave the target undisclosed until a suitable discussion channel is agreed.

Which output should we explore?

Share only information you are comfortable sending by email. Detailed sequences or proprietary data can be discussed through a suitable channel later.

Your details are emailed to GenoScan for a reply.

Market research / Resources

Ideas and market perspectives.

Explore published articles for ideas on IgY ingredients, formulation and the audiences you serve.

View all articles
GenoScan / NATRIVIGA

Where IgY development meets product application.

GenoScan Biosciences Limited works with supplement brands on IgY ingredient programs and OEM development. NATRIVIGA presents selected concepts in finished wellness formats.

01 / B2B PARTNER PLATFORM

GenoScan Biosciences

For teams sourcing IgY ingredients or developing an OEM product. Start with the application, technical requirements, format and target market.

Explore IgY ingredient families
02 / CONSUMER WELLNESS BRAND

NATRIVIGA

Finished-product examples show how selected IgY concepts can be presented in daily wellness formats. They give partners a view of application and product experience.

View application cases
Past collaboration referenceSmartpep

Brand examples provide application context. Ingredient specifications, availability and commercial scope are confirmed separately for each partner project.

Discuss a project
Start a conversation

Tell us what you want to build.

Choose IgY ingredients or OEM development. Share the application family, target market, format, expected volume and project stage.

Discuss a project